Not only a time-saving approach: Is it the time of subcutaneous formulation for daratumumab administration?

J Oncol Pharm Pract. 2021 Oct;27(7):1751-1752. doi: 10.1177/10781552211037974. Epub 2021 Aug 11.
No abstract available

Keywords: Daratumumab; multiple myeloma; subcutaneous administration.

MeSH terms

  • Antibodies, Monoclonal* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Humans
  • Multiple Myeloma* / drug therapy

Substances

  • Antibodies, Monoclonal
  • daratumumab